<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>67(2)</volume><submitter>Chen J</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Lattice and granular corneal dystrophy comprise two common TGFBI-associated autosomal dominant corneal disorders. Existing therapies are only temporizing and carry significant morbidity. Here, we develop a novel therapeutic approach using an adenine base editor (ABE) to correct common TGFBI mutations.&lt;h4>Method&lt;/h4>We generated two human corneal epithelial (HCE) cell models harboring a copy of the most common disease-causing TGBFI mutations, R124C or R555W. These lines were electroporated with an ABE8e-NG-encoding mRNA and guide RNAs targeting the mutations. The resulting A•T-to-G•C editing efficiencies and off-target (OT) effects were assessed by amplicon sequencing. GFP-expressing adeno-associated viruses (AAVs) with different capsid types were transduced into HCE cells a</pubmed_abstract><journal>Investigative ophthalmology &amp; visual science</journal><pagination>60</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12949465</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies.</pubmed_title><pmcid>PMC12949465</pmcid><pubmed_authors>Hou Z</pubmed_authors><pubmed_authors>Prasov L</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Ellis J</pubmed_authors><pubmed_authors>Blevins B</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Davison CW</pubmed_authors><pubmed_authors>Kong D</pubmed_authors><pubmed_authors>Presley W</pubmed_authors><pubmed_authors>Mian SI</pubmed_authors><pubmed_authors>Myers MT</pubmed_authors></additional><is_claimable>false</is_claimable><name>CRISPR Base Editing Correction of TGFBI Mutations in Autosomal Dominant Corneal Dystrophies.</name><description>&lt;h4>Purpose&lt;/h4>Lattice and granular corneal dystrophy comprise two common TGFBI-associated autosomal dominant corneal disorders. Existing therapies are only temporizing and carry significant morbidity. Here, we develop a novel therapeutic approach using an adenine base editor (ABE) to correct common TGFBI mutations.&lt;h4>Method&lt;/h4>We generated two human corneal epithelial (HCE) cell models harboring a copy of the most common disease-causing TGBFI mutations, R124C or R555W. These lines were electroporated with an ABE8e-NG-encoding mRNA and guide RNAs targeting the mutations. The resulting A•T-to-G•C editing efficiencies and off-target (OT) effects were assessed by amplicon sequencing. GFP-expressing adeno-associated viruses (AAVs) with different capsid types were transduced into HCE cells a</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-16T23:24:44.721Z</modification><creation>2026-07-12T03:11:18.486Z</creation></dates><accession>S-EPMC12949465</accession><cross_references><pubmed>41757824</pubmed><doi>10.1167/iovs.67.2.60</doi></cross_references></HashMap>